IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
May 2024 Vol.:30, Issue:5

Psoriasis – A Brief Review

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Shruti. R. Devarkonda*

Amepurva Forum's Nirant Institutes of Pharmacy, Boramani, Solapur, Maharashtra State, India

Submitted: 22 April 2024
Accepted: 28 April 2024
Published: 30 May 2024

Keywords: psoriasis, inflammation, chronic skin diseases, papules and plaques

ABSTRACT

Research on psoriasis pathogenesis has generally expanded understanding on pores and skin biology in general. In the previous 15 years, breakthroughs in the grasp of the pathogenesis of psoriasis have been translated into centered and particularly wonderful cures imparting indispensable insights into the pathogenesis of continual inflammatory illnesses with a dominant IL-23/Th17 axis. This evaluation discusses the mechanisms concerned in the initiation and improvement of the disease, as properly as the therapeutic choices that have arisen from the dissection of the inflammatory psoriatic pathways. Our dialogue starts through addressing the inflammatory pathways and key phone sorts initiating and perpetuating psoriatic inflammation. Next, we describe the function of genetics, related epigenetic mechanisms, and the interplay of the pores and skin plant life in the pathophysiology of psoriasis. Finally, we consist of a complete evaluation of well-established extensively reachable cures and novel focused drugs. Psoriasis is a ailment characterized by using the presence of papules and plaques over the floor of pores and skin with variable morphology, distribution and severity. The lesions of psoriasis are wonderful from these different entities and are classically very well-circumscribed, circular, purple papules or plaques with a grey or silvery-white, dry scale. In addition, the lesions are usually dispensed symmetrically on the scalp, elbows, knees, lumbosacral area, and in the physique folds. The oral manifestations of psoriasis may also contain the oral mucosa or the tongue. The dorsal floor of the tongue indicates attribute pink patches surrounded with a yellow-white border. The relationship between eye lesions and psoriasis are the modern-day findings in the literature.

1. Definition and Epidemiology

Psoriasis is a persistent inflammatory pores and skin ailment with a robust genetic predisposition and autoimmune pathogenic traits. The international incidence is about 2%, however varies in accordance to areas [1]. It suggests a decrease incidence in Asian and some African populations, and up to 11% in Caucasian and Scandinavian populations [2,3,4,5].

1.1. Clinical Classification

The dermatologic manifestations of psoriasis are varied; psoriasis vulgaris is additionally known as plaque-type psoriasis, and is the most general type. The phrases psoriasis and psoriasis vulgaris are used interchangeably in the scientific literature; nonetheless, there are vital distinctions amongst the one-of-a-kind medical subtype.

1.2. Psoriasis Vulgaris

About 90% of psoriasis instances correspond to persistent plaque-type psoriasis. The classical scientific manifestations are sharply demarcated, erythematous, pruritic plaques included in silvery scales. The plaques can coalesce and cowl giant areas of skin. Common areas encompass the trunk, the extensor surfaces of the limbs, and the scalp [6,7].



Figure No - 01

1.3. Inverse Psoriasis

Also known as flexural psoriasis, inverse psoriasis influences intertriginous locations, and is characterized clinically with the aid of barely erosive erythematous plaques and patches.



Figure No - 02

1.4. Guttate Psoriasis

Guttate psoriasis is a variant with an acute onset of small erythematous plaques. It typically impacts teens or adolescents, and is frequently caused through group-A streptococcal infections of tonsils. About one-third of sufferers with guttate psoriasis will boost plaque psoriasis in the course of their person lifestyles [8,9].



Figure No - 03

1.5. Pustular psoriasis

Pustular psoriasis is characterized with the aid of multiple, coalescing sterile pustules. Pustular psoriasis can be localized or generalized. Two wonderful localized phenotypes have been described: psoriasis pustulosa palmoplantar is (PPP) and acrodermatitis continua of Hallopeau. Both of them have an effect on the palms and feet; PPP is confined to the hands and soles, and ACS is extra distally placed at the pointers of fingers and toes, and impacts the nail apparatus. Generalized pustular psoriasis provides with an acute and unexpectedly

modern direction characterized via diffuse redness and sub-corneal pustules, and is regularly accompanied by systemic signs [10].



Figure No - 04

1.6. Comorbidities in Psoriasis

Psoriasis typically affects the skin, but may also affect the joints, and has been associated with a number of diseases. Inflammation is not limited to the psoriatic skin, and has been shown to affect different organ systems. Thus, it has been postulated that psoriasis is a systemic entity rather than a solely dermatological disease. When compared to control subjects, psoriasis patients exhibit increased hyperlipidemia, hypertension, coronary artery disease, type 2 diabetes, and increased body mass index. The metabolic syndrome, which comprises the aforementioned conditions in a single patient, was two times more frequent in psoriasis patients [11,12]. Coronary plaques are also twice as common in psoriasis patients when compared to control subjects [13]. Several large studies have shown a higher prevalence of diabetes and cardiovascular disease correlating with the severity of psoriasis [14,15,16,17,18]. There are divided opinions regarding the contribution of psoriasis as an independent cardiovascular risk factor [19,20]; however, the collective evidence supports that psoriasis independently increases risk for myocardial infarction, stroke, and death due to cardiovascular disease (CVD) [21,22,23,24,25,26,27,28]. In addition, the risk was found to apply also to patients with mild psoriasis to a lower extent [21,27].

Vascular inflammation assessed via 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) found psoriasis duration to be a negative predicting factor. It was suggested that the cumulative effects of low-grade chronic

inflammation might accelerate vascular disease development [29]. In a study by Metha et al., systemic and vascular inflammation in six patients with moderate to severe psoriasis was quantified by FDG-PET/CT. Inflammation foci were registered as expected in the skin, joints, and tendons. In addition, FDG uptake in the liver and aorta revealed subclinical systemic inflammation [30]. Furthermore, standardized uptake values were reduced in the liver, spleen, and aorta following treatment with Ustekinumab {Kim, 2018 #359}. A new biomarker to assess CVD risk in psoriasis patients was proposed by nuclear magnetic resonance spectroscopy [31]. The signal originating from glycan N-acetylglucosamine residues called Glyc A in psoriasis patients was associated with psoriasis severity and subclinical CVD, and was shown to be reduced in response to the effective treatment of psoriasis.

Psoriatic inflammation of the joints results in psoriatic arthritis (PsA). The skin manifestations generally precede PsA, which shares the inflammatory chronicity of psoriasis and requires systemic therapies due to a potential destructive progression. Psoriatic arthritis develops in up to 40% of psoriasis patients [32,33,34,35,36,37,38]; around 15% of psoriasis patients are thought to have undiagnosed PsA [39]. It presents clinically with dactylitis and enthesitis in oligoarticular or polyarticular patterns. The polyarticular variant is frequently associated with nail involvement [40]. Nails are specialized dermal appendages that can also be affected by psoriatic inflammation. Nail psoriasis is reported to affect more than half of psoriasis patients, and can present as the only psoriasis manifestation in 5–10% of patients [41]. The clinical presentation of nail psoriasis depends on the structure affected by the inflammatory process. Nail matrix involvement presents as pitting, leukonychia, and onychodystrophy, whereas inflammation of the nail bed presents as oil-drop discoloration, splinter hemorrhages, and onycholysis [42]. Psoriatic nail involvement is associated with joint involvement, and up to 80% of patients with PsA have nail manifestations [43,44].

2.Pathogenesis

The hallmark of psoriasis is sustained inflammation that leads to uncontrolled keratinocyte proliferation and dysfunctional differentiation. The histology of the psoriatic plaque suggests acanthosis (epidermal hyperplasia), which overlies inflammatory infiltrates composed of dermal dendritic cells, macrophages, T cells, and neutrophils. Neovascularization is moreover a exquisite feature. The inflammatory pathways energetic in plaque psoriasis and the rest of

the scientific versions overlap, then again moreover exhibit discrete variants that account for the one of a form phenotype and remedy effects.

2.1 Main Cytokines and Cell Types in Plaque Psoriasis

Disturbances in the innate and adaptive cutaneous immune responses are accountable for the improvement and sustainment of psoriatic irritation [53,54]. An activation of the innate immune gadget pushed with the aid of endogenous hazard alerts and cytokines usually coexists with an autoinflammatory perpetuation in some patients, and T cell-driven autoimmune reactions in others. Thus, psoriasis indicates qualities of an autoimmune ailment on an (auto)inflammatory historical past [55], with each mechanism overlapping and even potentiating one another.

2.2 Pathophysiology in Variants

Whereas the TNFα–IL23–Th17 axis performs a central position in T cell-mediated plaque psoriasis, the innate immune machine seems to play a extra outstanding function in the pustular variations of psoriasis [55]. Different direction mechanisms are related with wonderful psoriasis subtypes.

In guttate psoriasis, streptococcal superantigens are idea to stimulate the growth of T cells in the pores and skin [67]. It was once proven that there is a good-sized sequence homology between streptococcal M proteins and human keratin 17 proteins. Molecular mimicry may also play a position in sufferers with the primary histocompatibility HLA-Cw6 allele, seeing that CD8(+) T telephone IFN-γ responses had been elicited through K17 and M6 peptides in stated sufferers [68,69].

2.3 Autoimmunity in Psoriasis

Psoriasis shows clear autoimmune-related path mechanisms. This very important area of research will allow for a deeper understanding of to which extent autoantigen-specific T cells contribute to the development, chronification, and overall course of the disease.

2.4 Genetics

Psoriasis is a genetic thing that is supported with the aid of patterns of familial aggregation. First and second-degree loved ones of psoriasis sufferers have an elevated incidence of growing psoriasis, whilst monozygotic twins have a two to threefold accelerated threat in contrast to dizygotic twins [82,83]. Determining the particular impact of genetics in shaping innate and adaptive immune responses has validated frustration for psoriasis and different severe immune-mediated ailments [84,85]. The genetic editions related to psoriasis are concerned in distinctive organic processes, inclusive of immune features such as antigen presentation, inflammation, and keratinocyte biology [55].

2.5 Epigenetics

The quest for the lacking heritability related with psoriasis candidate genes has fueled the search for epigenetic modifications. Epigenetic mechanisms regulate gene expression except altering the genomic sequence; some examples include: lengthy noncoding RNA (lncRNA), microRNA (miRNA) silencing, and cytosine and guanine (CpG) methylation.

2.6 Microbiome

The pores and skin microbiome exerts a lively position in immune legislation and pathogen protection by way of stimulating the manufacturing of antibacterial peptides and thru biofilm formation. A differential colonizing microbiota in evaluation to wholesome pores and skin has been observed in countless dermatologic diseases, together with atopic dermatitis, psoriasis, and pimples vulgaris.It is hypothesized that an aberrant immune activation caused through pores and skin microbiota is worried in the pathogenesis of autoimmune diseases. For instance, there is developing proof that the steady-state microbiome performs a function in autoimmune illnesses such as in inflammatory bowel disorder.

2.7 Biologics

In the context of psoriasis treatment, modern use of the time period biologics refers to complicated engineered molecules which include monoclonal antibodies and receptor fusion proteins. Biologics are special from the above-described systemic treatment plans in that they goal particular inflammatory pathways and are administered subcutaneously (s.c.) (or

intravenously i.e., infliximab) on distinct weekly schedules. Biologics currently goal two pathways imperative in the improvement and chronicity of the psoriatic plaque: the IL-23/Th17 axis and TNF-α-signaling.

2.8 Biosimilars in Psoriasis

The introduction of biosimilars for special illnesses is revolutionizing the pharmaceutical arsenal at hand. As patents for many biologics face expiration, biosimilar variations of these pills are being developed, or are already coming into the market. A biosimilar is a organic product that should fulfill two requirements: it need to be exceptionally comparable to an permitted biologic product and have no clinically significant variations in safety, purity, or efficiency when in contrast with the reference product. Guidelines for the improvement and approval of biosimilars have been issued through the European Medicines Agency, the FDA, and the World Health Organization. There are presently eight adalimumab biosimilars, 4 infliximab biosimilars, and two etanercept biosimilars permitted in Europe. By decreasing the expenses of systemic cure for psoriasis patients, biosimilars may additionally make bigger get entry to biologics.

2.9 Drugs in the Research Pipeline

Tofacitinib is an oral Janus kinase (JAK) inhibitor presently permitted for the therapy of rheumatoid arthritis (RA) and PsA. Tofacitinib confirmed a 59% PASI seventy-five and 39% PASI ninety response charge at week 16, and used to be additionally tremendous for nail psoriasis; however, its development for psoriasis used to be halted for motives unrelated to safety. Upadacitinib is every other JAK inhibitor presently present process segment III scientific trials for the cure of psoriatic arthritis. Piclidenoson, an adenosine A3 receptor inhibitor, serlopitant, a neurokinin-1 receptor antagonist, and RORγt inhibitors are every being examined as oral redress for psoriasis . Two special biologics focused on IL-17 and one focused on IL-23 are being presently tested. In addition, there are presently thirteen registered section III medical trials checking out biosimilars for adalimumab (eight), infliximab (three), and etanercept (two).

2.10 Small-Molecule Therapies

In the previous years, an accelerated development in psoriasis remedies has resulted in superior focused organic drugs. Methotrexate (MTX), cyclosporin A, and retinoids are standard systemic therapy picks for psoriasis. All of the former are oral tablets with the exception of MTX, which is additionally accessible for subcutaneous administration. They will be quickly mentioned in this assessment .The part ends with an overview on dimethyl fumarate and apremilast, which are more recent tablets that have been permitted for psoriasis.

MTX is a folic acid analogue that inhibits DNA synthesis by way of blocking off thymidine and purine biosynthesis. The preliminary endorsed dose of 7.5–10 mg/weekly may additionally be elevated to a most of 25 mg/weekly .A current retrospective find out about pronounced profitable therapy response (defined through PASI limit of 50% to 75% and absolute DLQI value) used to be reached via 33%, 47%, and 64% of sufferers at three, six, and 12 months, respectively . There is conflicting proof concerning MTX effectiveness on psoriatic arthritis. A current eBook mentioned 22.4% of sufferers accomplished minimal arthritic ailment activity, and 27.2% reached a PASI seventy five at week 12 . Furthermore, HLA-Cw6 has been recommended as a workable marker for sufferers who may additionally gain from MTX cure. The most frequent facet consequences encompass nausea, leucopenia, and liver transaminase elevation. Despite the achievable aspect outcomes and its teratotoxicity, it stays a regularly used cost effective first-line.

3. Therapy

Psoriasis is a persistent relapsing disease, which regularly necessitates a long-term therapy. The desire of remedy for psoriasis is decided by way of ailment severity, comorbidities, and get entry to to fitness care. Psoriatic sufferers are often labeled into two groups: moderate or average to extreme psoriasis, relying on the scientific severity of the lesions, the share of affected physique floor area, and affected person fine of lifestyle . Clinical ailment severity and response to cure can be graded thru a wide variety of extraordinary scores. The PASI rating has been notably used in scientific trials, specifically these pertaining to the improvement of the biologic drugs, and will be used all through this review. Mild to reasonable psoriasis can be dealt with topically with a mixture of glucocorticoids, nutrition D analogues, and phototherapy. Moderate to extreme psoriasis regularly requires systemic treatment. The presence of comorbidities such as psoriasis arthritis is additionally

extraordinarily applicable in cure selection. In this review, we will tackle the systemic healing procedures as small-molecule (traditional and new) and biologic drugs.

4. Conclusion

Psoriasis is a complicated multifactorial disorder for which quite a number novel healing procedures have arisen in the previous years. In spite of the refinement of the focused therapies, psoriasis stays a treatable however so a ways no longer curable disease. The centered treatment plans exhibit excessive medical efficacy for the inhibition of IL-23 and IL-17. Some diploma of a power anti psoriatic impact by means of these treatment plans may want to be proven after drug discontinuation, and argue for sickness amendment idea . This necessary discovering will be accompanied up in ongoing and future studies. However, in different cases, an preliminary scientific response is solely brief lived, requiring therapy with a unique biologic. Clearly, extra lookup is required to reply the query of why the drug survival of some biologics is limited. The therapeutic arsenal for psoriasis is in all likelihood to extend in the close to future, with research on orally utilized new small molecules such as inhibitors concentrated on RORγt. In spite of the protection and efficacy of centered therapies, due to financial factors, dosage regimes, and unfavorable impact profiles, broader-acting capsules continue to be the mainstay of psoriasis systemic remedy in many medical eventualities round the world. The position of genetics stays to be elucidated now not solely in the context of predisposition to disease, however additionally in the profiling of wonderful psoriatic sorts based totally on cytokine signatures, and in figuring out remedy response markers. Clearly, psoriasis is presently the fantastic understood and the pleasant treatable Th17-biased continual inflammatory disease. After reaching first-rate scientific responses for the majority of sufferers with handy therapeutic approaches, the stratification of psoriasis sufferers to the optimum drug and making sure the sustainability of our redress are the main duties to be resolved.

5. Acknowledgement

I would like to express my vote of thanks to the management of Amepurva Forum’s , Nirant Institutes of Pharmacy, Boramani , Solapur, Maharashtra . I would also show gratitude towards my colleagues who have motivated to this review paper, - “Psoriasis – A brief Review. ”

References

1. Christophers E. Psoriasis—Epidemiology and clinical spectrum. *Clin. Exp. Dermatol.* 2001;26:314–320. doi: 10.1046/j.1365-2230.2001.00832.x. [PubMed] [CrossRef] [Google Scholar]
2. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *J. Investig. Dermatol.* 2013;133:377–385. doi: 10.1038/jid.2012.339. [PubMed] [CrossRef] [Google Scholar]
3. Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. *Int. J. Dermatol.* 1996;35:633–639. doi: 10.1111/j.1365-4362.1996.tb03687.x. [PubMed] [CrossRef] [Google Scholar]
4. Rachakonda T.D., Schupp C.W., Armstrong A.W. Psoriasis prevalence among adults in the united states. *J. Am. Acad. Dermatol.* 2014;70:512–516. doi: 10.1016/j.jaad.2013.11.013. [PubMed] [CrossRef] [Google Scholar]
5. Danielsen K., Olsen A.O., Wilsgaard T., Furberg A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. *Br. J. Dermatol.* 2013;168:1303–1310. doi: 10.1111/bjd.12230. [PubMed] [CrossRef] [Google Scholar]
6. Ortonne J., Chimenti S., Luger T., Puig L., Reid F., Trueb R.M. Scalp psoriasis: European consensus on grading and treatment algorithm. *J. Eur. Acad. Dermatol. Venereol.* 2009;23:1435–1444. doi: 10.1111/j.1468-3083.2009.03372.x. [PubMed] [CrossRef] [Google Scholar]
7. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. *N. Engl. J. Med.* 2009;361:496–509. doi: 10.1056/NEJMra0804595. [PubMed] [CrossRef] [Google Scholar]
8. Ko H.C., Jwa S.W., Song M., Kim M.B., Kwon K.S. Clinical course of guttate psoriasis: Long-term follow-up study. *J. Dermatol.* 2010;37:894–899. doi: 10.1111/j.1346-8138.2010.00871.x. [PubMed] [CrossRef] [Google Scholar]
9. Martin B.A., Chalmers R.J., Telfer N.R. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? *Arch. Dermatol.* 1996;132:717–718. doi: 10.1001/archderm.1996.03890300147032. [PubMed] [CrossRef] [Google Scholar]
10. Navarini A.A., Burden A.D., Capon F., Mrowietz U., Puig L., Koks S., Kingo K., Smith C., Barker J.N., Network E. European consensus statement on phenotypes of pustular psoriasis. *J. Eur. Acad. Dermatol. Venereol.* 2017;31:1792–1799. doi: 10.1111/jdv.14386. [PubMed] [CrossRef] [Google Scholar]
11. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Arch. Dermatol. Res.* 2006;298:321–328. doi: 10.1007/s00403-006-0703-z. [PubMed] [CrossRef] [Google Scholar]
12. Gerdes S., Mrowietz U., Boehncke W.H. Comorbidity in psoriasis. *Hautarzt.* 2016;67:438–444. doi: 10.1007/s00105-016-3805-3. [PubMed] [CrossRef] [Google Scholar]
13. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., Kaufmann R., Vogl T.J., Boehncke W.H. Psoriasis: A possible risk factor for development of coronary artery calcification. *Br. J. Dermatol.* 2007;156:271–276. doi: 10.1111/j.1365-2133.2006.07562.x. [PubMed] [CrossRef] [Google Scholar]
14. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., Troxel A.B. The risk of stroke in patients with psoriasis. *J. Investig. Dermatol.* 2009;129:2411–2418. doi: 10.1038/jid.2009.112. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Prodanovich S., Kirsner R.S., Kravetz J.D., Ma F., Martinez L., Federman D.G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. *Arch. Dermatol.* 2009;145:700–703. doi: 10.1001/archdermatol.2009.94. [PubMed] [CrossRef] [Google Scholar]
16. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006;296:1735–1741. doi: 10.1001/jama.296.14.1735. [PubMed] [CrossRef] [Google Scholar]
17. Ahlehoff O., Gislason G.H., Charlot M., Jorgensen C.H., Lindhardsen J., Olesen J.B., Abildstrom S.Z., Skov L., Torp-Pedersen C., Hansen P.R. Psoriasis is associated with clinically significant cardiovascular risk: A danish nationwide cohort study. *J. Intern. Med.* 2011;270:147–157. doi: 10.1111/j.1365-2796.2010.02310.x. [PubMed] [CrossRef] [Google Scholar]

18. Kimball A.B., Guerin A., Latremouille-Viau D., Yu A.P., Gupta S., Bao Y., Mulani P. Coronary heart disease and stroke risk in patients with psoriasis: Retrospective analysis. *Am. J. Med.* 2010;123:350–357. doi: 10.1016/j.amjmed.2009.08.022. [PubMed] [CrossRef] [Google Scholar]
19. Stern R.S. Psoriasis is not a useful independent risk factor for cardiovascular disease. *J. Investig. Dermatol.* 2010;130:917–919. doi: 10.1038/jid.2009.446. [PubMed] [CrossRef] [Google Scholar]
20. Stern R.S., Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. *J. Investig. Dermatol.* 2011;131:1159–1166. doi: 10.1038/jid.2010.399. [PubMed] [CrossRef] [Google Scholar]
21. Armstrong E.J., Harskamp C.T., Armstrong A.W. Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies. *J. Am. Heart Assoc.* 2013;2:e000062. doi: 10.1161/JAHA.113.000062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Gaeta M., Castelvecchio S., Ricci C., Pigatto P., Pellissero G., Cappato R. Role of psoriasis as independent predictor of cardiovascular disease: A meta-regression analysis. *Int. J. Cardiol.* 2013;168:2282–2288. doi: 10.1016/j.ijcard.2013.01.197. [PubMed] [CrossRef] [Google Scholar]
23. Gu W.J., Weng C.L., Zhao Y.T., Liu Q.H., Yin R.X. Psoriasis and risk of cardiovascular disease: A meta-analysis of cohort studies. *Int. J. Cardiol.* 2013;168:4992–4996. doi: 10.1016/j.ijcard.2013.07.127. [PubMed] [CrossRef] [Google Scholar]
24. Horreau C., Pouplard C., Brenaut E., Barnetche T., Misery L., Cribier B., Jullien D., Aractingi S., Aubin F., Joly P., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review. *J. Eur. Acad. Dermatol. Venereol.* 2013;27(Suppl. 3):12–29. doi: 10.1111/jdv.12163. [PubMed] [CrossRef] [Google Scholar]
25. Miller I.M., Ellervik C., Yazdanyar S., Jemec G.B. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. *J. Am. Acad. Dermatol.* 2013;69:1014–1024. doi: 10.1016/j.jaad.2013.06.053. [PubMed] [CrossRef] [Google Scholar]
26. Pietrzak A., Bartosinska J., Chodorowska G., Szepietowski J.C., Paluszkiewicz P., Schwartz R.A. Cardiovascular aspects of psoriasis: An updated review. *Int. J. Dermatol.* 2013;52:153–162. doi: 10.1111/j.1365-4632.2012.05584.x. [PubMed] [CrossRef] [Google Scholar]
27. Samarasekera E.J., Neilson J.M., Warren R.B., Parnham J., Smith C.H. Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis. *J. Investig. Dermatol.* 2013;133:2340–2346. doi: 10.1038/jid.2013.149. [PubMed] [CrossRef] [Google Scholar]
28. Xu T., Zhang Y.H. Association of psoriasis with stroke and myocardial infarction: Meta-analysis of cohort studies. *Br. J. Dermatol.* 2012;167:1345–1350. doi: 10.1111/bjd.12002. [PubMed] [CrossRef] [Google Scholar]
29. Egeberg A., Skov L., Joshi A.A., Mallbris L., Gislason G.H., Wu J.J., Rodante J., Lerman J.B., Ahlman M.A., Gelfand J.M., et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. *J. Am. Acad. Dermatol.* 2017;77:650–656.e3. doi: 10.1016/j.jaad.2017.06.028. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Mehta N.N., Yu Y., Saboury B., Foroughi N., Krishnamoorthy P., Raper A., Baer A., Antigua J., Van Voorhees A.S., Torigian D.A., et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18f]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): A pilot study. *Arch. Dermatol.* 2011;147:1031–1039. doi: 10.1001/archdermatol.2011.119. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Joshi A.A., Lerman J.B., Aberra T.M., Afshar M., Teague H.L., Rodante J.A., Krishnamoorthy P., Ng Q., Aridi T.Z., Salahuddin T., et al. Glyca is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. *Circ. Res.* 2016;119:1242–1253. doi: 10.1161/CIRCRESAHA.116.309637. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Ogdie A., Langan S., Love T., Haynes K., Shin D., Seminara N., Mehta N.N., Troxel A., Choi H., Gelfand J.M. Prevalence and treatment patterns of psoriatic arthritis in the UK. *Rheumatology.* 2013;52:568–575. doi: 10.1093/rheumatology/kes324. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Li R., Sun J., Ren L.M., Wang H.Y., Liu W.H., Zhang X.W., Chen S., Mu R., He J., Zhao Y., et al. Epidemiology of eight common rheumatic diseases in china: A large-scale cross-sectional survey in Beijing. *Rheumatology.* 2012;51:721–729. doi: 10.1093/rheumatology/ker370. [PubMed] [CrossRef] [Google Scholar]

34. Carneiro J.N., Paula A.P., Martins G.A. Psoriatic arthritis in patients with psoriasis: Evaluation of clinical and epidemiological features in 133 patients followed at the university hospital of Brasilia. *An. Bras. Dermatol.* 2012;87:539–544. doi: 10.1590/S0365-05962012000400003. [PubMed] [CrossRef] [Google Scholar]
35. Haroon M., Kirby B., FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. *Ann. Rheum. Dis.* 2013;72:736–740. doi: 10.1136/annrheumdis-2012-201706. [PubMed] [CrossRef] [Google Scholar]
36. Henes J.C., Ziupa E., Eisfelder M., Adamczyk A., Knaudt B., Jacobs F., Lux J., Schanz S., Fierlbeck G., Spira D., et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: A cross-sectional study. *Rheumatol. Int.* 2014;34:227–234. doi: 10.1007/s00296-013-2876-z. [PubMed] [CrossRef] [Google Scholar]
37. Mease P.J., Gladman D.D., Papp K.A., Khraishi M.M., Thaci D., Behrens F., Northington R., Fuiman J., Bananis E., Boggs R., et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. *J. Am. Acad. Dermatol.* 2013;69:729–735. doi: 10.1016/j.jaad.2013.07.023. [PubMed] [CrossRef] [Google Scholar]
38. Reich K., Kruger K., Mossner R., Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in germany: A prospective interdisciplinary epidemiological study of 1511 patients with Plaque-type psoriasis. *Br. J. Dermatol.* 2009;160:1040–1047. doi: 10.1111/j.1365-2133.2008.09023.x. [PubMed] [CrossRef] [Google Scholar]
39. Villani A.P., Rouzaud M., Sevrain M., Barnetche T., Paul C., Richard M.A., Beylot-Barry M., Misery L., Joly P., Le Maitre M., et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. *J. Am. Acad. Dermatol.* 2015;73:242–248. doi: 10.1016/j.jaad.2015.05.001. [PubMed] [CrossRef] [Google Scholar]
40. Stoll M.L., Zurakowski D., Nigrovic L.E., Nichols D.P., Sundel R.P., Nigrovic P.A. Patients with juvenile psoriatic arthritis comprise two distinct populations. *Arthritis Rheum.* 2006;54:3564–3572. doi: 10.1002/art.22173. [PubMed] [CrossRef] [Google Scholar]
41. Salomon J., Szepietowski J.C., Proniewicz A. Psoriatic nails: A prospective clinical study. *J. Cutan. Med. Surg.* 2003;7:317–321. doi: 10.1007/s10227-002-0143-0. [PubMed] [CrossRef] [Google Scholar]
42. Pasch M.C. Nail psoriasis: A review of treatment options. *Drugs.* 2016;76:675–705. doi: 10.1007/s40265-016-0564-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Langenbruch A., Radtke M.A., Krensel M., Jacobi A., Reich K., Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. *Br. J. Dermatol.* 2014;171:1123–1128. doi: 10.1111/bjd.13272. [PubMed] [CrossRef] [Google Scholar]
44. Maejima H., Taniguchi T., Watarai A., Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. *Int. J. Dermatol.* 2010;49:901–906. doi: 10.1111/j.1365-4632.2009.04452.x. [PubMed] [CrossRef] [Google Scholar]
45. Ellinghaus D., Ellinghaus E., Nair R.P., Stuart P.E., Esko T., Metspalu A., Debrus S., Raelson J.V., Tejasvi T., Belouchi M., et al. Combined analysis of genome-wide association studies for crohn disease and psoriasis identifies seven shared susceptibility loci. *Am. J. Hum. Genet.* 2012;90:636–647. doi: 10.1016/j.ajhg.2012.02.020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
46. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. *Nature.* 2007;447:661–678. doi: 10.1038/nature05911. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Yeung H., Takeshita J., Mehta N.N., Kimmel S.E., Ogdie A., Margolis D.J., Shin D.B., Attor R., Troxel A.B., Gelfand J.M. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. *JAMA Dermatol.* 2013;149:1173–1179. doi: 10.1001/jamadermatol.2013.5015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
48. Wan J., Wang S., Haynes K., Denburg M.R., Shin D.B., Gelfand J.M. Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study. *BMJ.* 2013;347:f5961. doi: 10.1136/bmj.f5961. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B., Jr., Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. *J. Am. Acad. Dermatol.* 1999;41:401–407. doi: 10.1016/S0190-9622(99)70112-X. [PubMed] [CrossRef] [Google Scholar]

50. Szepietowski J.C., Reich A. Pruritus in psoriasis: An update. *Eur. J. Pain.* 2016;20:41–46. doi: 10.1002/ejp.768. [PubMed] [CrossRef] [Google Scholar]
51. Fleming P., Bai J.W., Pratt M., Sibbald C., Lynde C., Gulliver W.P. The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials. *J. Eur. Acad. Dermatol. Venereol.* 2017;31:798–807. doi: 10.1111/jdv.13891. [PubMed] [CrossRef] [Google Scholar]
52. Sampogna F., Tabolli S., Abeni D. Living with psoriasis: Prevalence of shame, anger, worry, and problems in daily activities and social life. *Acta Derm. Venereol.* 2012;92:299–303. doi: 10.2340/00015555-1273. [PubMed] [CrossRef] [Google Scholar]
53. Di Meglio P., Villanova F., Nestle F.O. Psoriasis. *Cold Spring Harb. Perspect. Med.* 2014;4:6. doi: 10.1101/cshperspect.a015354. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of psoriasis: A comprehensive review. *J. Autoimmun.* 2015;64:66–73. doi: 10.1016/j.jaut.2015.07.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: A mixed autoimmune and autoinflammatory disease. *Curr. Opin. Immunol.* 2017;49:1–8. doi: 10.1016/j.coi.2017.07.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
56. Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. *J. Dermatol.* 2012;39:225–230. doi: 10.1111/j.1346-8138.2011.01483.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
57. Morizane S., Yamasaki K., Muhleisen B., Kotol P.F., Murakami M., Aoyama Y., Iwatsuki K., Hata T., Gallo R.L. Cathelicidin antimicrobial peptide ll-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. *J. Investig. Dermatol.* 2012;132:135–143. doi: 10.1038/jid.2011.259. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
58. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *J. Exp. Med.* 2005;202:135–143. doi: 10.1084/jem.20050500. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A., Arai N., Gallo R.L., Digiovanni J., Gilliet M. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type i interferons. *J. Exp. Med.* 2010;207:2921–2930. doi: 10.1084/jem.20101102. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Santini S.M., Lapenta C., Donati S., Spadaro F., Belardelli F., Ferrantini M. Interferon-α-conditioned human monocytes combine a TH1-orienting attitude with the induction of autologous TH17 responses: Role of IL-23 and IL-12. *PLoS ONE.* 2011;6:e17364. doi: 10.1371/journal.pone.0017364. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Hansel A., Gunther C., Ingwersen J., Starke J., Schmitz M., Bachmann M., Meurer M., Rieber E.P., Schakel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. *J. Allergy Clin. Immunol.* 2011;127:787–794. doi: 10.1016/j.jaci.2010.12.009. [PubMed] [CrossRef] [Google Scholar]
62. Nestle F.O., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of t lymphocytes and induction of th1 type cytokines. *J. Clin. Investig.* 1994;94:202–209. doi: 10.1172/JCI117308. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., Cornelissen F., Mus A.M., Florencia E., Prens E.P., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. *J. Immunol.* 2009;182:5836–5845. doi: 10.4049/jimmunol.0802999. [PubMed] [CrossRef] [Google Scholar]
64. Matsuzaki G., Umemura M. Interleukin-17 family cytokines in protective immunity against infections: Role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s. *Microbiol. Immunol.* 2018;62:1–13. doi: 10.1111/1348-0421.12560. [PubMed] [CrossRef] [Google Scholar]
65. Gaffen S.L. Structure and signalling in the IL-17 receptor family. *Nat. Rev. Immunol.* 2009;9:556–567. doi: 10.1038/nri2586. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
66. Lee J.S., Tato C.M., Joyce-Shaikh B., Gulen M.F., Cayatte C., Chen Y., Blumenschein W.M., Judo M., Ayanoglu G., McClanahan T.K., et al. Interleukin-23-independent IL-17 production regulates intestinal

epithelial permeability. *Immunity.* 2015;43:727–738. doi: 10.1016/j.immuni.2015.09.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
67. Leung D.Y., Travers J.B., Giorno R., Norris D.A., Skinner R., Aelion J., Kazemi L.V., Kim M.H., Trumble A.E., Kotb M., et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. *J. Clin. Investig.* 1995;96:2106–2112. doi: 10.1172/JCI118263. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
68. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Love T.J., Valdimarsson H. Peripheral blood t cell responses to keratin peptides that share sequences with streptococcal m proteins are largely restricted to skin-homing $CD8^+$ T cells. *Clin. Exp. Immunol.* 2004;138:83–93. doi: 10.1111/j.1365-2249.2004.00600.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
69. Diluvio L., Vollmer S., Besgen P., Ellwart J.W., Chimenti S., Prinz J.C. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. *J. Immunol.* 2006;176:7104–7111. doi: 10.4049/jimmunol.176.11.7104. [PubMed] [CrossRef] [Google Scholar]
70. Johnston A., Xing X., Wolterink L., Barnes D.H., Yin Z., Reingold L., Kahlenberg J.M., Harms P.W., Gudjonsson J.E. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. *J. Allergy Clin. Immunol.* 2017;140:109–120. doi: 10.1016/j.jaci.2016.08.056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Bissonnette R., Fuentes-Duculan J., Mashiko S., Li X., Bonifacio K.M., Cueto I., Suarez-Farinas M., Maari C., Bolduc C., Nigen S., et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. *J. Dermatol. Sci.* 2017;85:20–26. doi: 10.1016/j.jdermsci.2016.09.019. [PubMed] [CrossRef] [Google Scholar]
72. Wilsmann-Theis D., Schnell L.M., Ralser-Isselstein V., Bieber T., Schon M.P., Huffmeier U., Mossner R. Successful treatment with interleukin-17a antagonists of generalized pustular psoriasis in patients without IL36RN mutations. *J. Dermatol.* 2018;45:850–854. doi: 10.1111/1346-8138.14318. [PubMed] [CrossRef] [Google Scholar]
73. Goldminz A.M., Au S.C., Kim N., Gottlieb A.B., Lizzul P.F. Nf-kappab: An essential transcription factor in psoriasis. *J. Dermatol. Sci.* 2013;69:89–94. doi: 10.1016/j.jdermsci.2012.11.002. [PubMed] [CrossRef] [Google Scholar]
74. Boutet M.A., Nerviani A., Gallo Afflitto G., Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. *Int. J. Mol. Sci.* 2018;19:530. doi: 10.3390/ijms19020530. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
75. Sakkas L.I., Bogdanos D.P. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. *Autoimmun. Rev.* 2017;16:10–15. doi: 10.1016/j.autrev.2016.09.015. [PubMed] [CrossRef] [Google Scholar]
76. Mensah K.A., Schwarz E.M., Ritchlin C.T. Altered bone remodeling in psoriatic arthritis. *Curr. Rheumatol. Rep.* 2008;10:311–317. doi: 10.1007/s11926-008-0050-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
77. Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., Chamilos G., Feldmeyer L., Marinari B., Chon S., et al. The antimicrobial peptide ll37 is a T-cell autoantigen in psoriasis. *Nat. Commun.* 2014;5:5621. doi: 10.1038/ncomms6621. [PubMed] [CrossRef] [Google Scholar]
78. Arakawa A., Siewert K., Stohr J., Besgen P., Kim S.M., Ruhl G., Nickel J., Vollmer S., Thomas P., Krebs S., et al. Melanocyte antigen triggers autoimmunity in human psoriasis. *J. Exp. Med.* 2015;212:2203–2212. doi: 10.1084/jem.20151093. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
79. Fuentes-Duculan J., Bonifacio K.M., Hawkes J.E., Kunjravia N., Cueto I., Li X., Gonzalez J., Garcet S., Krueger J.G. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. *Exp. Dermatol.* 2017;26:1075–1082. doi: 10.1111/exd.13378. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
80. Cheung K.L., Jarrett R., Subramaniam S., Salimi M., Gutowska-Owsiak D., Chen Y.L., Hardman C., Xue L., Cerundolo V., Ogg G. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1A. *J. Exp. Med.* 2016;213:2399–2412. doi: 10.1084/jem.20160258. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

81. Yunusbaeva M., Valiev R., Bilalov F., Sultanova Z., Sharipova L., Yunusbayev B. Psoriasis patients demonstrate HLA-Cw*06:02 allele dosage-dependent T cell proliferation when treated with hair follicle-derived keratin 17 protein. *Sci. Rep.* 2018;8:6098. doi: 10.1038/s41598-018-24491-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
82. Farber E.M., Nall M.L., Watson W. Natural history of psoriasis in 61 twin pairs. *Arch. Dermatol.* 1974;109:207–211. doi: 10.1001/archderm.1974.01630020023005. [PubMed] [CrossRef] [Google Scholar]
83. Farber E.M., Nall M.L. The natural history of psoriasis in 5600 patients. *Dermatologica.* 1974;148:1–18. doi: 10.1159/000251595. [PubMed] [CrossRef] [Google Scholar]
84. Davidson A., Diamond B. Autoimmune diseases. *N. Engl. J. Med.* 2001;345:340–350. doi: 10.1056/NEJM200108023450506. [PubMed] [CrossRef] [Google Scholar]
85. Hayter S.M., Cook M.C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. *Autoimmun. Rev.* 2012;11:754–765. doi: 10.1016/j.autrev.2012.02.001. [PubMed] [CrossRef] [Google Scholar]
86. Bowcock A.M., Krueger J.G. Getting under the skin: The immunogenetics of psoriasis. *Nat. Rev. Immunol.* 2005;5:699–711. doi: 10.1038/nri1689. [PubMed] [CrossRef] [Google Scholar]
87. Sagoo G.S., Cork M.J., Patel R., Tazi-Ahnini R. Genome-wide studies of psoriasis susceptibility loci: A review. *J. Dermatol. Sci.* 2004;35:171–179. doi: 10.1016/j.jdermsci.2004.02.009. [PubMed] [CrossRef] [Google Scholar]
88. Elder J.T. Expanded genome-wide association study meta-analysis of psoriasis expands the catalog of common psoriasis-associated variants. *J. Investig. Dermatol. Symp. Proc.* 2018;19:S77–S78. doi: 10.1016/j.jisp.2018.09.005. [PubMed] [CrossRef] [Google Scholar]
89. Trembath R.C., Clough R.L., Rosbotham J.L., Jones A.B., Camp R.D., Frodsham A., Browne J., Barber R., Terwilliger J., Lathrop G.M., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. *Hum. Mol. Genet.* 1997;6:813–820. doi: 10.1093/hmg/6.5.813. [PubMed] [CrossRef] [Google Scholar]
90. Nair R.P., Stuart P.E., Nistor I., Hiremagalore R., Chia N.V., Jenisch S., Weichenthal M., Abecasis G.R., Lim H.W., Christophers E., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. *Am. J. Hum. Genet.* 2006;78:827–851. doi: 10.1086/503821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
91. Mallon E., Bunce M., Savoie H., Rowe A., Newson R., Gotch F., Bunker C.B. HLA-C and guttate psoriasis. *Br. J. Dermatol.* 2000;143:1177–1182. doi: 10.1046/j.1365-2133.2000.03885.x. [PubMed] [CrossRef] [Google Scholar]
92. Gudjonsson J.E., Karason A., Antonsdottir A., Runarsdottir E.H., Hauksson V.B., Upmanyu R., Gulcher J., Stefansson K., Valdimarsson H. Psoriasis patients who are homozygous for the Hla-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. *Br. J. Dermatol.* 2003;148:233–235. doi: 10.1046/j.1365-2133.2003.05115.x. [PubMed] [CrossRef] [Google Scholar]
93. Allen M.H., Ameen H., Veal C., Evans J., Ramrakha-Jones V.S., Marsland A.M., Burden A.D., Griffiths C.E., Trembath R.C., Barker J.N. The major psoriasis susceptibility locus psors1 is not a risk factor for late-onset psoriasis. *J. Investig. Dermatol.* 2005;124:103–106. doi: 10.1111/j.0022-202X.2004.23511.x. [PubMed] [CrossRef] [Google Scholar]
94. Berki D.M., Liu L., Choon S.E., David Burden A., Griffiths C.E.M., Navarini A.A., Tan E.S., Irvine A.D., Ranki A., Ogo T., et al. Activating card14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. *J. Investig. Dermatol.* 2015;135:2964–2970. doi: 10.1038/jid.2015.288. [PubMed] [CrossRef] [Google Scholar]
95. Hwu W.L., Yang C.F., Fann C.S., Chen C.L., Tsai T.F., Chien Y.H., Chiang S.C., Chen C.H., Hung S.I., Wu J.Y., et al. Mapping of psoriasis to 17q terminus. *J. Med. Genet.* 2005;42:152–158. doi: 10.1136/jmg.2004.018564. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
96. Jordan C.T., Cao L., Roberson E.D., Pierson K.C., Yang C.F., Joyce C.E., Ryan C., Duan S., Helms C.A., Liu Y., et al. PSORS2 is due to mutations in CARD14. *Am. J. Hum. Genet.* 2012;90:784–795. doi: 10.1016/j.ajhg.2012.03.012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

97. Tomfohrde J., Silverman A., Barnes R., Fernandez-Vina M.A., Young M., Lory D., Morris L., Wuepper K.D., Stastny P., Menter A., et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. *Science.* 1994;264:1141–1145. doi: 10.1126/science.8178173. [PubMed] [CrossRef] [Google Scholar]
98. Capon F., Novelli G., Semprini S., Clementi M., Nudo M., Vultaggio P., Mazzanti C., Gobello T., Botta A., Fabrizi G., et al. Searching for psoriasis susceptibility genes in italy: Genome scan and evidence for a new locus on chromosome 1. *J. Investig. Dermatol.* 1999;112:32–35. doi: 10.1046/j.1523-1747.1999.00471.x. [PubMed] [CrossRef] [Google Scholar]
99. De Cid R., Riveira-Munoz E., Zeeuwen P.L., Robarge J., Liao W., Dannhauser E.N., Giardina E., Stuart P.E., Nair R., Helms C., et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. *Nat. Genet.* 2009;41:211–215. doi: 10.1038/ng.313. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
100. Oh I.Y., de Guzman Strong C. The molecular revolution in cutaneous biology: EDC and locus control. *J. Investig. Dermatol.* 2017;137:e101–e104. doi: 10.1016/j.jid.2016.03.046. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
101. Riveira-Munoz E., He S.M., Escaramis G., Stuart P.E., Huffmeier U., Lee C., Kirby B., Oka A., Giardina E., Liao W., et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. *J. Investig. Dermatol.* 2011;131:1105–1109. doi: 10.1038/jid.2010.350. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
102. Elder J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. *Genes Immun.* 2009;10:201–209. doi: 10.1038/gene.2009.11. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
103. Tsoi L.C., Spain S.L., Ellinghaus E., Stuart P.E., Capon F., Knight J., Tejasvi T., Kang H.M., Allen M.H., Lambert S., et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. *Nat. Commun.* 2015;6:7001. doi: 10.1038/ncomms8001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
104. Yin X., Low H.Q., Wang L., Li Y., Ellinghaus E., Han J., Estivill X., Sun L., Zuo X., Shen C., et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. *Nat. Commun.* 2015;6:6916. doi: 10.1038/ncomms7916. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
105. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., Ding J., Li Y., Tejasvi T., Gudjonsson J.E., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat. Genet.* 2012;44:1341–1348. doi: 10.1038/ng.2467. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
106. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. *J. Immunol.* 2002;168:5699–5708. doi: 10.4049/jimmunol.168.11.5699. [PubMed] [CrossRef] [Google Scholar]
107. Andres R.M., Hald A., Johansen C., Kragballe K., Iversen L. Studies of jak/stat3 expression and signalling in psoriasis identifies STAT3-SER727 phosphorylation as a modulator of transcriptional activity. *Exp. Dermatol.* 2013;22:323–328. doi: 10.1111/exd.12128. [PubMed] [CrossRef] [Google Scholar]
108. Di Meglio P., Di Cesare A., Laggner U., Chu C.C., Napolitano L., Villanova F., Tosi I., Capon F., Trembath R.C., Peris K., et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced TH17 effector response in humans. *PLoS ONE.* 2011;6:e17160. doi: 10.1371/journal.pone.0017160. [PMC free article] [PubMed] [CrossRef] [Google Scholar]